



Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in Rapid Viral Load Reduction and High Viral Suppression Rates in Untreated HBeAg-Negative Subjects with Chronic Hepatitis B Virus Infection

Edward Gane¹, Kosh Agarwal², Alina Jucov³, Alexei Haceatrean³, Min Wu⁴, Kha Le⁴, Thanh Van⁴, Jen Rito⁴, Lawrence M. Blatt⁴, Sushmita Chanda⁴, Tse-I Lin⁴, Hardean E. Achneck⁴, Man-Fung Yuen⁵

1. Faculty of Medicine, University of Auckland, Auckland, New Zealand; 2. King's College Hospital, Institute of Liver Studies, London, United Kingdom; 3. ARENSIA Exploratory Medicine, Republican Clinical Hospital and Nicolae Testemitanu State University of Medicine and Pharmacy, Chișinău, Moldova; 4. Aligos Therapeutics, Inc., South San Francisco, United States; 5. Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China





Disclosure of Conflict of Interest


- Member of Scientific Advisory Board for Aligos, Assembly, AusperBio, Epigenetics Therapeutics, Gilead, GSK, Janssen, Roche, Surrozen, VIR, Virion, Precision Biosciences, Tune Therapeutics.
- Speaker for AbbVie, Roche Diagnostics.



Background


THERAPEUTICS

- Importance of HBV DNA Suppression: Achieving undetectable levels of HBV DNA using most sensitive assays crucial for effective viral control, reducing risk of liver disease progression. [WHO 2015, AASLD 2018, EASL 2017].
- ALG-000184: a prodrug of a novel CAM, ALG-001075, with potent in vitro anti-HBV activity through a dual mechanism-of-action (MOA):



Background

- ALG-000184-201 Study: An ongoing Phase 1 study has shown favorable safety and potent antiviral activity in treatment naive or current not treated chronic HBV infection subjects receiving 300 mg ALG-000184 monotherapy ≤ 92 weeks [AASLD 2024 poster]:
 - Significant Reductions: Multiple log declines in HBV DNA, RNA and all HBV antigen levels were detected;
 - No Breakthrough: No virologic breakthrough was observed in any subjects.
- Emerging Data: Efficacy and safety data in HBeAg-negative subjects receiving 300 mg ALG-000184 monotherapy for ≤ 96 weeks.



Baseline Characteristics in TN/CNT HBeAg-Negative Subjects 300 mg ALG-000184 monotherapy for ≤ 96 weeks

Baseline Characteristics	TN/CNT HBeAg-negative subjects (N=11)
Age, years, mean (SD)	48.5 (3.1)
Male, N (%)	6 (55)
Asian, N (%)	3 (27)
BMI, kg/m ² , mean (SD)	26.0 (1.1)
HBV Genotype B/C, N (%)	B:2(18), C:1(9), D:7(64), A:1(9)
HBV DNA, log ₁₀ IU/mL, median (SD)	4.3 (0.2)
HBV RNA, log ₁₀ copies/mL, median (SD)	2.0 (0.3)
HBsAg, log ₁₀ IU/mL, median (SD)	3.5 (0.2)
HBcrAg, log ₁₀ U/mL, mean (SD)	3.1 (0.3)
ALT, U/L, mean (SD)	35 (14.5)


Treatment Naïve (TN) subjects are defined as participants who have never received treatment with HBV antiviral medicines (NA, interferon [IFN]), or investigational anti-HBV agents including a CAM; Current-not-treated (CNT) subjects are defined as participants who have not been on treatment with approved (NA, IFN) or investigational HBV antiviral medicines within 6 months prior to randomization




Majority were non-Asian (8/11) Low-level viremia of HBV prior to dosing with ALG-000184

Mean HBV DNA Level $300 \text{ mg ALG}-000184 \text{ monotherapy for } \leq 96 \text{ weeks}$

SEM




Individual HBV DNA Levels 300 mg ALG-000184 monotherapy for ≤ 96 weeks





*One subject had transient HBV DNA increase from < LLOQ to 39 IU/mL at Week 72. At the subsequent visit (Week 76) HBV DNA was < LLOQ (10 IU/mL) and maintained this level during 300 mg ALG-000184 monotherapy.

Individual Time to Reach HBV DNA < LLOQ or < LLOD 300 mg ALG-000184 monotherapy for \leq 96 weeks




Time to HBV DNA suppression is dependent on baseline HBV DNA level 100% subjects achieved HBV DNA < LLOQ (10 IU/mL) at Week 20 100% subjects achieved < LLOD (4.29 IU/mL) by Week 80 No virologic breakthrough on ALG-000184 monotherapy


Mean HBV RNA Level $300 \text{ mg ALG}-000184 \text{ monotherapy for } \leq 96 \text{ weeks}$

n/N

SEM



Individual HBcrAg & HBsAg Changes from Baseline 300 mg ALG-000184 Monotherapy for ≤ 96 weeks



Mean HBcrAg change from baseline -0.3 \log_{10} U/mL; maximum decline 0.7 \log_{10} U/mL; 6/11 (55%) TN/CNT HBeAg-negative subjects had HBcrAg reduction \geq 0.5 \log_{10} U/mL.

Safety 300 mg ALG-000184 monotherapy for ≤ 96 weeks

	TN/CNT HBeAg-negative subjects
Numbers of subjects with	N=11
at least one TEAE, n (%)	6 (55)
SAE	0
TEAE leading to study drug discontinuation	0
TEAE Grade ≥3	2 ALT/AST elevations (n=1) Cholesterol and triglycerides increase (n=1)

300 mg ALG-000184 monotherapy for ≤ 96 weeks has favorable safety profile 1 Grade ≥3 TEAE of cholesterol/triglycerides increase.
1 Grade ≥3 TEAE of ALT/AST elevation with preserved synthetic and excretory functions not considered clinical concerning by ALT Flare Committee. Both ≥3 TEAEs resolved in setting of continuedALG-000184 dosing .



Summary

300 mg ALG-000184 monotherapy in TN/CNT HBeAg-negative subjects for ≤ 96 weeks demonstrated:

- A favorable safety profile
- Rapid and profound suppression in HBV DNA and HBV RNA:
 - All subjects achieved HBV DNA < LLOQ (10 IU/mL) by Week 20 and achieved < LLOD (4.29 IU/mL) by Week 80.
 - Sustained HBV RNA < LLOQ (10 copies/mL) by Week 8 for all subjects.
 - Significant declines in HBcrAg levels
 - No virologic breakthrough was observed in any subject.
- No HBsAg reductions observed in HBeAg negative patients, suggesting that most HBsAg in derived from integrated HBs gene rather than cccDNA.



Conclusions

- These results suggest that 300 mg ALG-000184 monotherapy achieves faster and more pronounced HBV DNA reduction than historically observed with nucleos(t)ide analogues, with no evidence of breakthrough
- ALG-000184 monotherapy could become a favorable option for chronic suppressive therapy in patients with chronic HBV infection.



Sincere gratitude to all individuals and organizations that contributed to this HBV data presentation.

- To the study participants and their families for their willingness to engage in this important research;
- -To the dedication of the clinical site staff who facilitated the study.
- -To the CRO Novotech for their invaluable insights and support.

These contributions have been essential to the success of this research.

